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Abstract
Cholangiocarcinoma is suspected based on signs of biliary obstruction, abnormal liver function tests, elevated tumor
markers (carbohydrate antigen 19-9 and carcinoembryonic antigen), and ultrasonography showing a bile stricture or a mass,
especially in intrahepatic cholangiocarcinoma. Magnetic resonance imaging (MRI) or computed tomography (CT) is
performed for the diagnosis and staging of cholangiocarcinomas. However, differentiation of an intraductal cholangio-
carcinoma from a hypovascular metastasis is limited at imaging. Therefore, reasonable exclusion of an extrahepatic primary
tumor should be performed. Differentiating between benign and malignant bile duct stricture is also difficult, except when
metastases are observed. The sensitivity of fluorodeoxyglucose positron emission tomography is limited in small, infiltrative,
and mucinous cholangiocarcinomas. When the diagnosis of a biliary stenosis remains indeterminate at MRI or CT,
endoscopic imaging (endoscopic or intraductal ultrasound, cholangioscopy, or optical coherence tomography) and tissue
sampling should be carried out. Tissue sampling has a high specificity for diagnosing malignant biliary strictures, but
sensitivity is low. The diagnosis of cholangiocarcinoma is particularly challenging in patients with primary sclerosing
cholangitis. These patients should be followed with yearly tumor markers, CT, or MRI. In the case of dominant stricture,
histological or cytological confirmation of cholangiocarcinoma should be obtained. More studies are needed to compare the
accuracy of the various imaging methods, especially the new intraductal methods, and the imaging features of malignancy
should be standardized.
Current review
The published literature has been reviewed after a
systematic search in PubMed for the terms ‘‘cholan-
giocarcinoma’’, ‘‘diagnosis’’, and ‘‘imaging’’. This
review includes current consensus statements [1,2],
meta-analysis [3], published clinical guidelines [4],
and information systems [5,6]. Recommendations are
based on the levels of evidence according to the
National Comprehensive Cancer Network (NCCN)
[4].
Clinical features of cholangiocarcinomas
Cholangiocarcinomas occur in the hilar region in
about 65% of cases, in the distal common bile duct
in 20%, and as an intrahepatic lesion in 15% [7,8].
Macroscopically, cholangiocarcinomas are usually
categorized in three types: exophytic or mass-forming,
infiltrative or periductal, and polypoid or intraductal
[9]. This last-mentioned type, also known as biliary
papillomatosis or intraductal papillary mucinous neo-
plasm of the bile ducts (IPMN-B), has a better
prognosis than the other two types [10,11]. Histolo-
gically, IPMN-B resembles intraductal papillary neo-
plasm of the pancreas.
Patients with hilar and extrahepatic cholangiocarci-
nomas usually present with symptoms of biliary
obstruction, including painless jaundice, pale stools,
dark urine, and pruritis.
Other symptoms that occur in patients with cho-
langiocarcinomas include malaise, weight loss, and
abdominal pain. These non-specific symptoms
usually appear after the disease is advanced, but
may be the only symptoms in patients with intrahe-
patic cholangiocarcinomas. Cholangitis is an unusual
presentation [1,12]. Hepatomegaly, tumor mass, or
dilated gallbladder may be observed at clinical exam-
ination.
In patients with primary sclerosing cholangitis,
cholangiocarcinoma can be suspected when the pa-
tient complains of increasing jaundice, pruritis, weight
loss, and abdominal pain, or when a rapidly increasing
serum bilirubin level is observed [8]. However, these
symptoms are not more frequent in patients with
cholangiocarcinoma than in those without malig-
nancy, except when cholangiocarcinoma is detected
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within one year of the diagnosis of primary sclerosing
cholangitis [13,14].
Laboratory studies
Biochemical tests typically suggest biliary obstruction,
with elevations in total and direct bilirubin, alkaline
phosphatase, 5?-nucleotidase, and gamma-glutamyl-
transferase. Aspartate aminotransferase and alanine
aminotransferase may be normal initially. Chronic
biliary obstruction often leads to hepatic dysfunction
with elevated aminotransferases [5].
Tumor markers
The value of tumor markers in the diagnosis of
cholangiocarcinomas remains controversial. The
most commonly used markers are carbohydrate anti-
gen 19-9 (CA 19-9) and carcinoembryonic antigen
(CEA). In patients with sclerosing cholangitis, the
reported sensitivity and specificity of elevated CA 19-
9 levels are 50%100% and 50%98%, respectively
[8]. Various cut-off values have been proposed,
generally between 100 U/ml and 200 U/ml. In a
recent retrospective study of 208 patients with scler-
osing cholangitis, including 14 patients with cholan-
giocarcinoma, Levy et al. [15] observed that CA 19-9
had an area under the ROC curve of 0.95 for
diagnosing cholangiocarcinoma, giving a sensitivity
of 79% and a specificity of 98%, with a cut-off value
of 129 U/ml. However, in this series, only two of the
14 patients with cholangiocarcinoma were candidates
for intervention with intent to cure. This means that
CA 19-9 only identifies patients with advanced,
unresectable cholangiocarcinomas. This conclusion
has been reinforced in a recent study in patients with
primary sclerosing cholangitis. In this study, 6 of the 8
patients with primary sclerosing cholangitis and
cholangiocarcinomas had early-stage tumors. The
AUROC of CA 19-9 in this study was only 0.655.
In patients without primary sclerosing cholangitis, the
sensitivity of a CA 19-9 level above 100 U/ml in
diagnosing cholangiocarcinoma is 53%67%, with a
specificity of 76%87% [1618].
High levels of CEA are often observed in gastro-
intestinal cancers, especially in colorectal carcinomas.
High CEA levels may also be observed in cholangio-
carcinomas. Several authors have suggested that
the diagnostic yield of CEA in the detection of cho-
langiocarcinoma is lower than that of CEA [18].
The reported sensitivity and specificity of CEA are
33%84% and 33%100%, respectively [18,19].
The usual cut-off is 5 ng/ml. The combined use of
CEA and CA 19-9 may improve the diagnosis of
cholangiocarcinoma [20], but this has not been
reproduced in all studies [21]. Both CEA and CA
19-9 have been measured in bile from patients with
benign and malignant bile duct diseases, but results
are contradictory and no consistent differences have
been found [18]. It is concluded that both CA 19-9
and CEA can be elevated in cholangiocarcinoma.
However, these markers can be elevated in other
cancers, in cholestasis in the absence of malignancy
and following liver injury, and, moreover, they have a
rather low sensitivity, especially CEA. Therefore,
measurements of CA 19-9 and CEA should not be
used alone for diagnosing cholangiocarcinomas
[1,16,22]. In unexplained biliary disease, CA 19-9
levels 100 UI/ml are considered suspicious for
cholangiocarcinoma in the absence of an inflamma-
tory process [18]. In patients with primary sclerosing
cholangitis, yearly surveillance with CA 19-9 is
carried out at many centers and a cut-off value of
180 UI/ml is often used even if patients with CA 19-9
above this level may already have advanced cholan-
giocarcinomas [8,23].
In patients with chronic hepatitis C, intrahepatic
cholangiocarcinoma or combined hepatocarcinoma
and cholangiocarcinoma may cause elevated alpha-
fetoprotein levels [24]. It has been estimated
that about 10% of hepatic masses with elevated
lectin-reactive alpha-fetoprotein levels are cholangio-
carcinomas or combined hepatocarcinomas and cho-
langiocarcinomas rather than hepatocarcinomas [25].
Finally, several new, potentially useful tumor mar-
kers, including mucins (MUC5AC) [26], are being
studied [27] and serum proteomic profiling is produ-
cing encouraging results [28]. The utility of these
methods awaits further evaluation.
Imaging
Ultrasonography
Ultrasonography is usually the first examination for
biliary obstruction or suspected liver disease. Intra-
hepatic cholangiocarcinoma may be identified as mass
lesions. In contrast, hilar and extrahepatic cholangio-
carcinoma are often infiltrative lesions that are diffi-
cult to detect. At ultrasonography, non-union of the
dilated right and left hepatic ducts may be seen
without an identifiable mass [9,29]. However, nodular
or irregular wall-thickening and polypoid intraluminal
masses may be seen. The reported sensitivity of
ultrasonography in detecting ductal masses or mural
thickening in hilar and extrahepatic cholangiocarci-
noma is up to 87%96% in some series, but depends
on the skill of the investigator [30,31]. The specificity
is unknown.
Computed tomography
Computed tomography (CT) can show bile duct
dilatation and a tumor mass, bile duct wall thickening,
or intraductal tissue in exophytic, infiltrative, and
polypoid cholangiocarcinomas, respectively. Multide-
tector CT may challenge the role of magnetic
resonance imaging (MRI) in the diagnosis of
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cholangiocarcinoma because of its high spatial resolu-
tion [32,33]. Hyperenhancement of the stenosed duct
during the portal venous phase has been considered to
be a sign of malignancy, but has a low specificity
(19%) as an isolated finding [34,35].
Magnetic resonance imaging
MRI with magnetic resonance cholangiopancreato-
graphy (MRCP) is usually considered the modality of
choice in the diagnosis of cholangiocarcinoma be-
cause of its high contrast resolution, multiplanar
capability, and its ability to determine the parenchy-
mal, biliary, and vascular extension [23]. Several
studies, including a meta-analysis, have shown that
MRI has a sensitivity and a specificity 90% in
diagnosing biliary obstruction [3,36,37]. The accu-
racy of MRI in diagnosing a malignant biliary stricture
is lower and variable according to the authors
(sensitivity of 48%88% and specificity of 71%
95%) [3,36,38,39]. It is important to perform con-
ventional unenhanced and contrast-enhanced MRI in
addition to MRCP to differentiate between benign
and malignant bile duct strictures [40].
Intrahepatic cholangiocarcinomas are often exo-
phytic masses that are large when discovered. The
lesions are hypointense relative to liver parenchyma
on T1-weighted images. On T2-weighted images,
they are slightly hyperintense when containing abun-
dant fibrosis and strongly hyperintense when contain-
ing mainly necrosis or mucous secretion [41]. On
gadolinium-enhanced MRI, the lesions are hypovas-
cular and show progressive and concentric filling with
contrast material. Associated findings include hepatic
capsular retraction, vascular encasement that may
lead to lobar atrophy, and dilatation of peripheral
bile ducts. An intrahepatic cholangiocarcinoma may
be difficult to differentiate from a metastasis (espe-
cially a metastasis from a foregut adenocarcinoma) at
imaging and at histology [9]. When an intrahepatic
mass presumed to be a cholangiocarcinoma is ob-
served at imaging, upper and lower gastrointestinal
endoscopy has been recommended to exclude an
extrahepatic primary gastrointestinal tumor [4]. At
histology, immunostaining for cytokeratins 7 and 20
helps to differentiate between intrahepatic cholangio-
carcinoma and metastasis from colon cancer [42]. An
inflammatory pseudotumor may also sometimes be
difficult to differentiate from an intrahepatic cholan-
giocarcinoma at imaging, but may regress sponta-
neously [43].
Endoscopic ultrasound
It has been reported that endoscopic ultrasound
(EUS) improves the diagnosis between malignant
and benign strictures relative to MRCP and CT
[36,44]. Endoscopic ultrasound can be used for
fine-needle aspiration of strictures with variable re-
ported sensitivities of 25%91% and specificities of
89%100% [4549].
Cholangiography
Because of their invasiveness, endoscopic retrograde
cholangiopancreatography (ERCP) and percutaneous
transhepatic cholangiography are replaced by MRCP,
CT, and EUS in assessing the morphology of the bile
ducts in patients with suspected biliary obstruction
[2,50]. To distinguish benign from malignant biliary
strictures, however, ERCP can be used to provide
tissue samples with different methods, including
brush cytology, fine-needle aspiration, and transpa-
pillary biopsy. These sampling methods are highly
specific (100%) for diagnosing a malignant tumor,
but have a low sensitivity of 46%73% [19,39,51,52].
The sensitivity can be improved by combining the
sampling methods at the expense of an increase in
the duration of the procedure and an increase in the
needed expertise [5355]. Moreover, the negative
predictive value remains low. The sensitivity of brush
cytology can be further improved by detecting chro-
mosomal abnormalities with advanced cytological
methods, including digital image analysis and fluo-
rescence in situ hybridization [56].
Intraductal ultrasound, cholangioscopy, and optical
coherence tomography
Emerging intraductal imaging methods include in-
traductal ultrasound, cholangioscopy, and optical
coherence tomography. Intraductal ultrasound has
high sensitivity and specificity in the diagnosis of
malignant biliary strictures (sensitivity 89%95%,
specificity 86%91%) [38,39,44,57,58].
Peroral cholangioscopy has been less studied. Only
the surface of the lesions is analyzed with this method,
which is further limited by the fragility of the
cholangioscopes [59]. Biopsies can be performed
through the cholangioscope, but adequate sampling
remains challenging because of the small size of the
instruments and the limited maneuverability of the
long baby endoscope [59,60]. Alternatively, percuta-
neous transhepatic cholangioscopy can be performed,
but a large transhepatic access is needed [61].
Optical coherence tomography is a new optical
imaging method. It is analogous to ultrasound ima-
ging but uses infrared light rather than acoustic
energy. Optical coherence tomography has an axial
resolution of 10 mm, i.e. 10-fold better than that of
high-frequency ultrasound. However, its depth pene-
tration is limited to approximately 1 mm versus
10 mm for a 20 MHz ultrasound probe. Only
preliminary results on the use of optical coherence
tomography in the biliary tree are available [62].
The use of these intraductal diagnostic methods
should be further validated by assessing their repro-
ducibility, standardizing the diagnostic features of
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malignancy, and comparing the accuracy of the
different techniques [63,64].
Positron emission tomography
Fluorodeoxyglucose positron emission tomography
(FDG PET) permits the detection of cholangiocarci-
nomas because of the high uptake of glucose and the
low activity of glucose-6-phosphatase in cholangio-
carcinoma [65]. Several studies have shown a sensi-
tivity and specificity 90% for PET in the diagnosis
of cholangiocarcinomas [6669]. However, it has
recently been recognized that the sensitivity of PET
is limited in small, infiltrative, and mucinous cholan-
giocarcinomas [65,70,71]. In the study by Anderson
et al. [65], the sensitivity of PET was 85% in nodular
cholangiocarcinomas, but only 18% in infiltrative
cholangiocarcinomas. As many hilar and extrahepatic
cholangiocarcinomas are infiltrative, these tumors are
not readily detected with PET. PET has a reported
specificity of 80%100% [65,67,68]. A much lower
specificity of 33% has been reported by Petrowsky
et al. in extrahepatic cholangiocarcinomas [71]. The
specificity of PET is limited because infectious and
inflammatory lesions may show a high FDG uptake
[70]. The use of delayed imaging 2 h after injection of
the tracer has been recommended to differentiate
cholangiocarcinomas from inflammatory lesions
[72,73].
Globally, the accuracy of PET was not better than
that of CT in the Petrowsky et al. study [71]. The use
of PET to diagnose cholangiocarcinomas in primary
sclerosing cholangitis remains controversial [69,74].
Because of false-positive and false-negative results,
Fevery et al. [74] consider that PET is not a reliable
method for the early diagnosis of cholangiocarcinoma
in patients with primary sclerosing cholangitis. Rather
than being useful for the diagnosis of cholangiocarci-
noma, PET (PET/CT) is particularly valuable in
detecting unsuspected distant metastases [71].
Characterization of proximal biliary stenoses
Isolated hilar obstruction not caused by trauma or
lithiasis is often malignant and presumed to corre-
spond to cholangiocarcinoma. However, non-trau-
matic inflammatory strictures may occur and are
difficult to differentiate from malignancy [75,76]. At
CT and MRI, signs of malignancy include an abrupt,
irregular, and asymmetric stricture, a mass lesion or
eccentric thickening of the bile duct (3 mm) with
hyperenhancement during the portal venous phase,
vascular invasion or stenosis, lymph node enlargement
and metastases [36,77]. However, with the exception
of metastases, isolated imaging features are not
specific. In some studies, it has been reported that
up to 27%75% of the patients with benign proximal
biliary strictures had a discrete mass at imaging
[75,76,78]. It is therefore important to assess the
combination of imaging findings to improve the
diagnostic accuracy [77].
‘‘Local’’ imaging methods, including EUS and
intraductal imaging, may improve the differentiation
between benign and malignant strictures, mainly by
better showing the penetration of the tumor into
surrounding tissue. Rosch et al. [36] studied 50
patients with suspected biliary strictures. The sensi-
tivity for diagnosing malignancy of MRCP (90%), CT
(90%), EUS (80%), and ERCP (90%) did not differ
significantly, nor did specificity (65%, 55%, 80%, and
70%, respectively). By contrast, in the study by
Domagk et al. [38], which included 30 patients with
suspected biliary strictures, there were significant
differences in sensitivity between MRI (48%), CT
(76%), EUS (81%), and ERCP with intraductal
ultrasound (95%). The specificity of the different
imaging methods did not differ significantly (78%
89%). These studies have limitations. Patients with
biliary and pancreatic lesions were included. The
MRI examinations did not include contrast-enhanced
sequences and some examinations were performed
after stent placement.
Further studies are needed to assess the role of the
imaging methods in differentiating between benign
and malignant strictures. However, when a doubt
exists about the diagnosis of a proximal biliary
stricture at CT or MRI, ‘‘local imaging’’ should be
performed because it has high spatial resolution and
offers the possibility of tissue sampling.
Conclusions
The diagnosis of cholangiocarcinoma remains diffi-
cult, despite the multiple diagnostic methods avail-
able. Further studies comparing the accuracy of the
various imaging methods, especially the new intra-
ductal methods, are needed, and the imaging features
of malignancy should be standardized. Currently, no
single imaging method emerges for the diagnosis of
cholangiocarcinoma. Because no high-powered ran-
domized clinical trials are available for assessing the
accuracy of the various methods in the diagnosis of
cholangiocarcinoma, and only limited evidence comes
from meta-analysis, the quality of evidence is low
(category 2A according to the NCCN categories of
evidence).
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